461418-05-3

Basic information

• Product Name: (4Z/E)-4-methoxyimino-1-[(2’-methyl-1,1’-biphenyl-4-yl)carbonyl]-L-proline
• Synonyms: (4Z/E)-4-methoxyimino-1-[(2’-methyl-1,1’-biphenyl-4-yl)carbonyl]-L-proline
• CAS NO: 461418-05-3
• Molecular Weight: 352.39
• Mol File: 461418-05-3.mol
• Article Data: 11

Chemical Properties

• CAS DataBase Reference: (4Z/E)-4-methoxyimino-1-[(2’-methyl-1,1’-biphenyl-4-yl)carbonyl]-L-proline(CAS DataBase Reference)
• NIST Chemistry Reference: (4Z/E)-4-methoxyimino-1-[(2’-methyl-1,1’-biphenyl-4-yl)carbonyl]-L-proline(461418-05-3)
• EPA Substance Registry System: (4Z/E)-4-methoxyimino-1-[(2’-methyl-1,1’-biphenyl-4-yl)carbonyl]-L-proline(461418-05-3)

Safety Data

• Hazardous Substances Data: 461418-05-3(Hazardous Substances Data)

Upstream product

• 84348-37-8 N-tert-butoxycarbonyl-4-oxo-L-proline 
• 13726-69-7 (2S,4R)-4-hydroxy-1-[(2-methylpropan-2-yl)oxycarbonyl]pyrrolidine-2-carboxylic acid 
• 461418-07-5 1-tert-butyl-2-methyl (2S,4EZ)-4-(methoxyimino)pyrrolidine-1,2-dicarboxylate 
• 364077-88-3 (4EZ)-1-(tert-butoxycarbonyl)-4-(methoxyimino)-L-proline 
• 5748-43-6 4-(2-methylphenyl)benzoic acid 
• 16419-60-6 2-Methylphenylboronic acid 
• 863976-38-9 1-(2’-methyl-1,1’-biphenyl-4-yl)carbonyl-4-oxo-L-proline 
• 593-56-6 N-methoxylamine hydrochloride 
• 461418-01-9 (4Z/E,2S)-methyl-1[(2’-methyl-1,1‘-biphenyl-4-yl)-carbonyl]-4-methoxyimino pyrrolidine-2-carboxylate 

Downstream Products

• 461418-01-9 (4Z/E,2S)-methyl-1[(2’-methyl-1,1‘-biphenyl-4-yl)-carbonyl]-4-methoxyimino pyrrolidine-2-carboxylate 

Relevant articles and documents

Differential effects of oxytocin receptor antagonists, atosiban and nolasiban, on oxytocin receptor-mediated signaling in human amnion and myometrium

One of the most established roles of oxytocin (OT) is in inducing uterine contractions and labor. Apart from inducing contractions, our recent studies showed that OT can also activate proinflammatory pathways in both human myometrial and amnion cells, whi

BIOMARKERS FOR OXYTOCIN RECEPTOR ANTAGONIST THERAPY

The disclosure provides compositions and methods for determining the propensity of a subject (e.g., a female human subject) undergoing embryo transfer therapy to benefit from administration of an oxytocin receptor antagonist, as well as for treating such

CRYSTALLINE (3Z,5S)-5-(HYDROXYMETHYL)-1-[(2'-METHYL-1,1'-BIPHENYL-4-YL)CARBONYL]PYRROLIDIN-3-ONE O-METHYLOXIME USEFUL IN METHODS OF TREATING CONDITIONS RELATED TO THE OT-R ACTIVITY

Crystalline (3Z,5S)-5-(hydroxymethyl)-1-[(2'-methyl-1,1'-biphenyl-4-yl)carbonyl]pyrrolidin-3-one O-methyloxime is disclosed. A pharmaceutical composition containing the crystalline compound and methods for treating conditions related to the OT-R activity,